Is Hims & Hers Health Stock a Buy Now?
Share prices of direct-to-consumer healthcare company Hims & Hers Health (NYSE: HIMS) started hot in 2023, doubling from $6 per share to $12. But the stock has lost momentum, drifting backward since peaking, and is now flat for the year. Was the early success a fluke? Or is it just the market testing investors' conviction in the name?
Here is why this stock is an opportunity you don't want to miss.
Hims & Hers is a digital healthcare platform where patients can consult professionals for several conditions and receive personalized scripts sent to their homes. Hims & Hers is a very young corporation; the business was founded in 2017. Still, it's grown subscribers to 1.3 million, and its total in the second quarter was a 74% year-over-year increase.
Source Fool.com
